Summary
The systemic elimination of nicardipine has been studied by an initial oral administration of nicardipine followed 1.25 h later by intravenous injection of the deuterium-labelled molecule (D3 nicardipine).
To check that intravenous kinetics was not modified by the oral administration, an i.v. injection of unlabelled nicardipine (D0 nicardipine) was also given. The study was carried out in six healthy male volunteers, aged between 24 and 27 years, according to a Latin square cross-over design.
Similar values were found for each kinetic parameter after i.v. administration regardless of whether it was administered alone by that route or with an oral dose. The plasma level-time curves of nicardipine were described by a three open compartment model. The total plasma clearance was about 800 ml/min, the volume of distribution was of the order of 1 l/kg and the half-life of β-elimination ranged from 4 to 5 h. The elimination rate constant β was independent of the route of administration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Albert KS, Smith RB (1983) Bioavailability assessment as influenced by variation in drug absorption. In: Albert KS (ed) Drug absorption and disposition: Statistical consideration. American Pharmaceutical Association, pp 87–100
Banzet O, Colin JN, Thibonner M, Singlas E, Alexandre JM, Corvol P (1983) Acute antihypertensive effect and pharmacokinetics of a tablet preparation of nifedipine. Eur J Clin Pharmacol 24: 145–150
Delchier JC, Guerret M, Vidon N, Dubray C, Lavene D (1988) Influence of digestive secretions and food on intestinal absorption of nicardipine. Eur J Clin Pharmacol 34: 165–171
Eichelbaum M, Somogyi A, von Unruh GE, Dengler HJ (1987) Simultaneous determination of the intravenous and oral pharmacokinetic parameters of d,l-verapamil using isotope- labelled verapamil. Eur J Pharmacol 19: 133–137
Gibaldi M, Perrier D (1982) Pharmacokinetics, Marcel Dekker, New York
Gomeni R (1984) PHARM. An interactive graphic program for individual and population pharmacokinetic parameter estimation. Comput Biol Med 14: 25–34
Graham DJM, Dow RJ, Hall DJ, Alexander OF, Mroszczak EJ, Freedman D (1985) The metabolism and pharmacokinetics of nicardipine hydrochloride in man. Br J Clin Pharmacol 20: 23S-28S
Higuchi S, Shiobara Y (1980) Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilatator, in various species. Xenobiotica 10: 447–454
Higuchi S, Shiobara Y (1980) Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. Xenobiotica 10: 889–896
Kleinbloesem CH, Van Brummelen P, Van de Linde JA, Voogd PJ, Breimer DD (1984) Nifedipine: kinetics and dynamics in healthy subjects. Clin Pharmacol Ther 35: 742–749
Mikus G, Fischer C, Heuer B, Langen C, Eichelbaum M (1987) Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration. Br J Clin Pharmacol 24: 561–569
Pang KS, Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5: 625–653
Raemsch KD, Sommer J (1984) Pharmacokinetics and metabolism of nitrendipine. In: Nitrendipine. Scriabine A, Vanov S, Deck K. Urban & Schwarzenberg, Baltimore Munich, pp 409–421
Silke B, Grahams DJM, Verma SP, Reynolds G, Frais MA, Finlayson JR, Taylor SH (1986) Pharmacokinetic, haemodynamic and radionuclide studies with nicardipine in coronary artery disease. Eur J Clin Pharmacol 29: 651–657
Takenaka T, Usuda S, Nomura T, Maeno H, Sado T (1976) Vasodilator profile of a new 1,4-dihydropyridine derivative, 2,6-dimethyl-4-(3-nitrophenyl-1,4-dihydropyridine-3,5-dicarbox ylic acid 3-[2-(N-benzyl-N-methylamino)] ethyl ester 5-methyl ester hydrochloride (YC 93. Arzneimittelforsch 26: 2172–2178
Thuillez C, Guerret M, Duhaze P, Lhoste F, Kiechel JR, Giudicelli JF (1984) Nicardipine: Pharmacokinetics and effects on carotid and brachial blood flows in normal volunteers. Br J Clin Pharmacol 18: 837–847
Urien S, Albengres E, Comte A, Kiechel JR, Tillement JP (1985) Plasma protein binding and erythrocyte partitioning of nicardipine in vitro. J Cardiovasc Pharmacol 7: 891–898
Wagner JG, Ling TL, Mroszczak EJ, Freedman D, Wu A, Huang B, Massey IJ, Roe RR (1987) Single intravenous dose and steady-state oral dose pharmacokinetics of nicardipine in healthy subjects. Biopharm Drug Dispos 8: 133–148
Wilkinson GR, Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18: 377–390
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Guerret, M., Cheymol, G., Hubert, M. et al. Simultaneous study of the pharmacokinetics of intravenous and oral nicardipine using a stable isotope. Eur J Clin Pharmacol 37, 381–385 (1989). https://doi.org/10.1007/BF00558504
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558504